BsUFA III Meeting Improvements To Cut Requests, Improve Biosimilar Development Efficiency
New biosimilar Type 2a meeting will facilitate faster development, stakeholders said, but one representative also warned that the inspection backlog must be eliminated in order for the US FDA to meet the new user fee program commitments.
You may also be interested in...
Biosimilars continue their erratic behavior, with the low numbers driving big swings.
Product sampling and remote records requests accounted for most import alerts and drug GMP warning letters over the past year – and may play key role post-pandemic.
Six supplement categories based on submission content will be created with review goals between three and 10 months.